Kisspeptin-10: The Neuropeptide Behind GnRH, IVF and Sexual Desire

Kisspeptin-10 (KP-10) is the shortest biologically active fragment of the kisspeptin family of neuropeptides encoded by the KISS1 gene. Its 10-amino-acid sequence – Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2 (YNWNSFGLRF-NH2) – represents the C-terminal decapeptide that is essential for receptor binding and activation. It acts as a potent endogenous agonist of GPR54, also known as KISS1R, a Gq/11-coupled G-protein coupled receptor (PubChem CID 25077588).

The KISS1 gene was first isolated in 1996 by Lee and colleagues, published in the Journal of the National Cancer Institute, as a metastasis-suppressor gene in human melanoma cells on chromosome 6. The gene product was named metastin for its anti-metastatic properties, and it would have remained an oncology footnote had parallel receptor science not intervened. In 2003, two groups – de Roux in Nature Genetics and Seminara in the New England Journal of Medicine – independently reported that loss-of-function mutations in GPR54 caused hypogonadotropic hypogonadism in humans, while gain-of-function mutations caused precocious puberty. This discovery reframed the KISS1 gene product from a cancer curiosity into the master gatekeeper of reproductive function.

The KISS1 prepropeptide (145 amino acids) is cleaved into fragments of varying length: kisspeptin-54 (the full-length active peptide), kisspeptin-14, kisspeptin-13, and kisspeptin-10. All share the same C-terminal decapeptide sequence required for KISS1R binding, but they differ in circulating half-life and pharmacokinetic behaviour. Kisspeptin-54 has a terminal half-life of approximately 28 minutes; kisspeptin-10’s is approximately 3-4 minutes.

Property	Detail
Full name	Kisspeptin-10 (KP-10)
Sequence	Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2 (YNWNSFGLRF-NH2)
Length	10 amino acids (C-terminal amidation required)
PubChem CID	25077588
Gene	KISS1 (chromosome 1q32.1; originally identified on chromosome 6 in melanoma suppression)
Receptor	GPR54 / KISS1R (Gq/11-coupled GPCR)
Plasma half-life	Approximately 3-4 minutes
Gene discovery	Lee et al. 1996, JNCI (melanoma metastasis suppressor)
GPR54 breakthrough	de Roux 2003 (Nature Genetics) / Seminara 2003 (NEJM): loss-of-function mutations cause hypogonadotropic hypogonadism

Kisspeptin-10 is part of a broader cluster of nootropic and neuropeptide compounds covered on this site. For the cross-category overview, see the nootropic and neuropeptide compounds hub.

The bottom line: Kisspeptin-10 is the minimal active fragment of a gene product discovered in cancer biology that turned out to be the master upstream switch controlling the reproductive hormone axis, identified through independent human genetic evidence in 2003.

Kisspeptin-10 binds to KISS1R (GPR54) on GnRH neurons in the hypothalamus, triggering a Gq/11-mediated signalling cascade that depolarises the neurons through activation of TRPC-like cationic channels. This stimulates pulsatile release of gonadotropin-releasing hormone (GnRH), which in turn drives luteinising hormone (LH) and follicle-stimulating hormone (FSH) secretion from the anterior pituitary. LH and FSH then act on the gonads to stimulate sex steroid production and gametogenesis.

Kisspeptin neurons are concentrated in two hypothalamic regions: the arcuate nucleus (ARC) and the anteroventral periventricular nucleus (AVPV). ARC kisspeptin neurons are now recognised as the GnRH pulse generator, with their intrinsic oscillatory activity driving the pulsatile GnRH secretion pattern essential for normal reproductive function. AVPV kisspeptin neurons mediate the pre-ovulatory LH surge in females. Together, these populations integrate sex steroid feedback from the periphery with metabolic status, photoperiod, and developmental stage to gate reproductive competence.

Tachyphylaxis and desensitisation

A critical pharmacological property of kisspeptin-10 is receptor desensitisation with chronic exposure. Continuous kisspeptin signalling leads to tachyphylaxis – a progressive reduction in GnRH and gonadotropin response. This means kisspeptin-10 does not simply “turn on” the reproductive axis in a sustained way. Pulsatile or intermittent administration maintains efficacy, while continuous exposure can paradoxically suppress the axis it is designed to stimulate. This property has direct implications for any therapeutic application and was cited by the FDA in its analysis preceding the PCAC review.

The bottom line: Kisspeptin-10 is the upstream trigger for the entire reproductive hormone cascade, acting through a specific receptor on GnRH neurons, but chronic exposure causes receptor desensitisation that can paradoxically suppress the axis.

IVF and oocyte maturation (Imperial College London)

The most advanced clinical research on kisspeptin comes from the Dhillo and Abbara groups at Imperial College London, who conducted the first-into-human kisspeptin studies in men (2005) and women (2007). Their programme has focused on using kisspeptin-54 (the longer fragment, not KP-10) as a physiological trigger for oocyte maturation in IVF, replacing the conventional hCG trigger that carries risk of ovarian hyperstimulation syndrome (OHSS).

In a Phase 2, multi-dose, open-label, randomised trial of 60 women at high OHSS risk (2013-2014 at Hammersmith Hospital, published in Journal of Clinical Investigation 2014), kisspeptin-54 successfully triggered oocyte maturation in 51 of 53 participants, with 12 pregnancies and no cases of OHSS. A subsequent 2015 report confirmed 30 healthy babies born using this approach. Abbara and colleagues demonstrated in studies published between 2015-2018 that kisspeptin was associated with the most favourable OHSS-risk profile compared to hCG and GnRH agonist triggers.

HPG axis stimulation and diagnostic use

Jayasena and colleagues, writing in the Journal of Clinical Endocrinology and Metabolism in 2011, reported that kisspeptin-10 stimulated LH in healthy male volunteers and increased both pulse frequency and amplitude, establishing KP-10 as the pharmacologically relevant shorter fragment for investigating pulse dynamics. Kisspeptin-10 has been used in hospital-based research protocols to distinguish between transient delayed puberty and permanent hypogonadotropic hypogonadism, and in investigational studies of hypothalamic amenorrhea.

Metastasis suppression

Kisspeptin-10 retains activity from its original KISS1 gene context as a metastasis suppressor. In preclinical work, KP-10 has been shown to inhibit tumour angiogenesis by suppressing Sp1-mediated VEGF expression and FAK/Rho GTPase activation. A 2025 study published in Scientific Reports demonstrated that KP-10 treatment of triple-negative breast cancer cells reduced viability and migration, induced a dose-dependent upregulation of KISS1 mRNA (suggesting a positive feedback loop), reversed epithelial-mesenchymal transition markers, and activated both intrinsic and extrinsic apoptotic pathways. These anti-cancer properties add biological complexity to a compound primarily studied for reproductive function.

Neuroimaging: kisspeptin and sexual brain processing

A research line largely absent from peptide content coverage is the Dhillo group’s fMRI neuroimaging work demonstrating that kisspeptin directly modulates limbic brain activity in humans. In a 2017 randomised, double-blinded, crossover study published in the Journal of Clinical Investigation, Comninos, Dhillo, and colleagues administered kisspeptin-54 or placebo to 29 healthy heterosexual men while they viewed sexual, couple-bonding, negative, and neutral images during functional MRI. Kisspeptin enhanced brain activity in the anterior and posterior cingulate and left amygdala in response to sexual images – structures known to express kisspeptin receptors and previously associated with sexual arousal in physiological imaging studies.

A follow-up 2018 JCI Insight study by the same group found that kisspeptin modulated resting-state brain connectivity, specifically the default mode network (DMN). The degree of DMN modulation by kisspeptin correlated with increased limbic activity in response to sexual stimuli (globus pallidus r = 0.500, P = 0.005; cingulate r = 0.475, P = 0.009) and predicted reduced sexual aversion (r = -0.499, P = 0.006). Kisspeptin also enhanced connectivity between mood-regulating structures including the amygdala-cingulate and hippocampus-cingulate pathways. This established kisspeptin as one of the very few reproductive hormones with demonstrated direct effects on resting brain architecture in humans, positioning it at the intersection of endocrinology and neuropsychiatry.

Hypoactive sexual desire disorder (HSDD)

Building on the neuroimaging work, Mills, Dhillo, and colleagues published a randomised clinical trial in JAMA Network Open in February 2023 testing kisspeptin-54 in men diagnosed with HSDD – a condition affecting approximately 8% of men that currently has no licensed pharmacological treatment. In this double-blinded, crossover trial, 32 men with HSDD received 75-minute intravenous infusions of kisspeptin-54 (1 nmol/kg/h) or placebo at visits separated by at least seven days, with fMRI performed during exposure to sexual video stimuli.

Kisspeptin significantly modulated brain activity in key structures of the sexual-processing network compared to placebo, and secondary analyses showed a 56% increase in penile tumescence in response to sexual stimuli (mean difference 0.28 units, 95% CI 0.04-0.52, P = 0.02) and increased self-reported happiness about sex (mean difference 0.63 points, 95% CI 0.10-1.15, P = 0.02). Kisspeptin was well tolerated with no adverse events reported and no effects on general mood or anxiety. The authors concluded that these data provide the first evidence that kisspeptin modulates sexual brain processing in men with HSDD and suggest kisspeptin has potential as the first pharmacological treatment for male low sexual desire. Preliminary results from a parallel trial in women have also been reported as positive.

Research area	Key findings	Evidence tier
IVF oocyte maturation	KP-54: 51/53 successful, 12 pregnancies, no OHSS (Dhillo/Abbara, Imperial)	Phase 2 human (KP-54, not KP-10)
LH/FSH stimulation in men	KP-10 and KP-54 both stimulate LH, increase pulse frequency	Human (healthy volunteers)
Hypothalamic amenorrhea	Kisspeptin administration restored gonadotropin pulsatility in women with FHA	Human (investigational)
Sexual brain processing (fMRI)	KP-54 enhanced limbic activity in cingulate and amygdala (n=29, JCI 2017). Modulated resting DMN connectivity (JCI Insight 2018)	Human RCT (healthy volunteers)
HSDD treatment	KP-54: 56% increase in penile tumescence, increased happiness about sex vs placebo (n=32, JAMA Network Open 2023)	Human RCT (HSDD patients)
Metastasis suppression	KP-10 inhibits angiogenesis, reverses EMT, induces apoptosis in cancer cells	Preclinical (in vitro and mouse xenograft)
GnRH pulse generation	ARC kisspeptin neurons are the GnRH pulse generator; kisspeptin antagonist suppresses LH pulsatility	Preclinical (in vivo)

The bottom line: Kisspeptin has genuine human clinical data across two distinct therapeutic domains – reproductive medicine (IVF oocyte maturation, HPG axis stimulation) and psychosexual neuroscience (fMRI-confirmed limbic modulation, HSDD treatment) – primarily from the Imperial College London programme, but the strongest evidence uses kisspeptin-54 rather than kisspeptin-10, no completed Phase III trial exists for any indication, and the HSDD programme remains at an early stage with small sample sizes.

Kisspeptin-10 was nominated for inclusion on the 503A bulks list for the treatment of secondary hypogonadism in men. The FDA placed it on Category 2 (significant safety concerns) in September 2023. On October 29, 2024, the PCAC reviewed kisspeptin-10 alongside ibutamoren mesylate, L-theanine, and ipamorelin. The FDA had recommended against inclusion, and the committee voted accordingly: kisspeptin-10 was not placed on the 503A bulks list.

The FDA’s analysis cited several factors weighing against inclusion: no applicable USP or NF monograph, kisspeptin-10 is not a component of any FDA-approved drug, the evidence for efficacy in secondary hypogonadism was insufficient, the tachyphylaxis concern with chronic dosing, and the overall balance of physicochemical characterisation, historical use evidence, effectiveness data, and safety information. For the broader context of how the PCAC process works, see the Category 1 vs Category 2 explainer.

Jurisdiction	Status
FDA (USA)	Not approved. PCAC voted against 503A inclusion October 29, 2024. Category 2 (as of September 2023). Not on 503A bulks list
MHRA (UK)	Not licensed. Used in academic research protocols at Imperial College London
TGA (Australia)	Not approved
WADA	Not individually listed. S2 category (peptide hormones) broadly defined and may encompass GnRH-stimulating compounds

For a wider view of peptide regulation across jurisdictions, see the guides for the US, the UK and Australia.

The bottom line: Kisspeptin-10 is one of the few peptides in this cluster that has been explicitly reviewed and rejected by the PCAC for 503A inclusion, making its US compounding pathway currently closed.

Kisspeptin has a generally favourable acute safety profile based on the Imperial College human studies and other academic protocols. In healthy volunteers and IVF patients, common effects are consistent with the expected pharmacology: transient flushing, mild injection site reactions, and hormonal fluctuations from acute gonadotropin surges.

The primary safety considerations are pharmacological rather than toxicological. Tachyphylaxis (receptor desensitisation) with chronic daily dosing means that the compound’s efficacy diminishes with sustained use, and paradoxical HPG axis suppression is possible. For IVF applications, the risk of OHSS is substantially lower than with hCG triggers based on published comparison data, but is not zero. Hormonal fluctuations from acute gonadotropin surges are an inherent effect of the mechanism, not an adverse reaction.

A 2017 preclinical study by Zhang and colleagues using kisspeptin-10 in rats reported cardiac findings including irregular contractile patterns, increased fibrosis around heart cells, and mitochondrial structural changes. This signal is not well-characterised in humans and was observed at research doses in an animal model, but it represents an identified preclinical concern that has not been systematically evaluated in long-term human studies.

The long-term safety profile of kisspeptin as a chronic therapy (as opposed to single-injection IVF triggering or short-term diagnostic use) is not established. For information on evaluating the quality of any research peptide, see the certificate of analysis guide.

The bottom line: Kisspeptin-10 appears safe for acute and short-term use based on academic trial data, but chronic-use safety is unestablished, tachyphylaxis is an inherent pharmacological limitation, and a preclinical cardiac signal remains incompletely characterised.

Kisspeptin-10 occupies a unique position in the neuropeptide cluster. Unlike Semax (nootropic/neurotrophic), Selank (anxiolytic/immunomodulatory), DSIP (sleep/stress), Cerebrolysin (neurotrophic mixture), VIP (immunomodulatory/pulmonary), or Dihexa (synaptogenic), kisspeptin-10’s primary function is reproductive neuroendocrine regulation. Its inclusion in the neuropeptide cluster reflects its hypothalamic neuropeptide identity and its regulatory significance rather than direct cognitive effects.

The most relevant comparison compound outside this cluster is gonadorelin (synthetic GnRH), which acts one step downstream in the same cascade. Gonadorelin holds FDA Category 1 status on the 503A list, placing it in a more favourable regulatory position than kisspeptin-10 despite targeting the same axis. The difference is that gonadorelin was previously FDA-approved (as Lutrepulse, now discontinued for commercial reasons), giving it a regulatory track record that kisspeptin-10 lacks.